| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1093/OXFORDJOURNALS.AJE.A116427 |
| P953 | full work available at URL | http://aje.oxfordjournals.org/cgi/content/abstract/136/10/1184 |
| P698 | PubMed publication ID | 1476141 |
| P2093 | author name string | R. Harris | |
| A. S. Whittemore | |||
| J. Itnyre | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 1184-1203 | |
| P577 | publication date | 1992-11-01 | |
| 1992-11-15 | |||
| P1433 | published in | American Journal of Epidemiology | Q4744243 |
| P1476 | title | Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group | |
| P478 | volume | 136 |
| Q35654685 | 15. Cancers attributable to reproductive factors in the UK in 2010 |
| Q34503833 | A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State |
| Q64130667 | A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer |
| Q40571606 | A model for estimating ovarian cancer risk: application for preventive oophorectomy |
| Q79433480 | A new 'publication bias': the mode of publication |
| Q48835641 | A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment |
| Q28213056 | A prospective study of postmenopausal hormone use and ovarian cancer risk |
| Q30431721 | A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study |
| Q74688260 | A systematic review and meta‐analysis of family history and risk of ovarian cancer |
| Q38719860 | Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling |
| Q46343579 | Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience |
| Q40511770 | Adverse effects of fertility drugs |
| Q51939298 | An appeal for statistical rigour |
| Q71730007 | An extended 10-day course of clomiphene citrate (CC) in women with CC-resistant ovulatory disorders |
| Q34345107 | Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk |
| Q55111427 | Anthropometric and Other Risk Factors for Ovarian Cancer in a Case‐Control Study |
| Q37194644 | Assessing Ovarian Cancer Risk When Considering Elective Oophorectomy at the Time of Hysterectomy |
| Q83504649 | Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy--a challenge for the surgeon |
| Q30277151 | Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors |
| Q37356693 | Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy |
| Q44687996 | Assisted reproduction in patients with early-stage ovarian malignancies |
| Q35670871 | Assisted reproductive technology in the new millennium: part II. |
| Q36394471 | Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence |
| Q71200492 | Association of BRCA1 expression with gonadotropin-responsive cells |
| Q37882038 | Association of positive Chlamydia trachomatis and Chlamydia pneumoniae immunoglobulin-γ titers with increasing age |
| Q38087982 | Biomarkers for Early Detection of Ovarian Cancer |
| Q35565269 | Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort |
| Q37982899 | Borderline ovarian tumours |
| Q35815854 | Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. |
| Q43062979 | Breast Cancer Risk After Use of Fertility Drugs: Stimulating New Controversy |
| Q34718774 | Breast and ovarian cancer incidence after infertility and in vitro fertilisation |
| Q40747946 | Breast cancer prevention through modulation of endogenous hormones |
| Q34464582 | Breast-feeding and drug exposure |
| Q81521580 | Breast-feeding initiation in low-income women: Role of attitudes, support, and perceived control |
| Q34307858 | Breast-feeding the last born child and risk of ovarian cancer |
| Q35690911 | Breastfeeding and maternal health outcomes: a systematic review and meta-analysis |
| Q57560003 | Breastfeeding and the risk of epithelial ovarian cancer in an Italian population |
| Q40125259 | Breastfeeding, ovulatory years, and risk of multiple sclerosis. |
| Q36029756 | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
| Q40855040 | Cancer chemoprevention. A new way to treat cancer before it happens. |
| Q36240519 | Cancer in women after assisted reproductive technology |
| Q74627359 | Cancer in women with infertility |
| Q44370973 | Cancer incidence in a cohort of infertile women who underwent in vitro fertilization |
| Q37288901 | Cancer risk after exposure to treatments for ovulation induction |
| Q33985177 | Cancer risk associated with early and late maternal age at first birth |
| Q35131946 | Cancer risks associated with the diagnosis of infertility |
| Q33841144 | Cancer screening in the elderly population |
| Q33584787 | Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer |
| Q47701058 | Chemoprevention of Hereditary Ovarian Cancer |
| Q91906673 | Chemotherapy Resistance in Advanced Ovarian Cancer Patients |
| Q72476914 | Childbearing and risk of ovarian cancer |
| Q84141991 | Clinical-genetic care of BRCA-mutation carrier women: prevention, diagnosis and therapy |
| Q24240690 | Clomiphene citrate for unexplained subfertility in women |
| Q43474119 | Cohort studies: marching towards outcomes |
| Q37590233 | Components of family history associated with women's disease perceptions for cancer: a report from the Family Healthware™ Impact Trial |
| Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
| Q34477390 | Contemporary management of ovarian cancer |
| Q34644721 | Contraception Methods, Beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer |
| Q77209279 | Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer |
| Q53701146 | Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women? |
| Q33942835 | Current strategies for prevention, detection, and treatment of ovarian cancer. |
| Q37551696 | Current understanding of risk factors for ovarian cancer |
| Q43817012 | Descriptive epidemiology of ovarian cancer in the United States, 1992-1997 |
| Q44559179 | Determinants of trends in breast-feeding indicators in Nigeria, 1999-2013. |
| Q38499888 | Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and meta-analysis |
| Q40689801 | Douching, Talc Use, and Risk of Ovarian Cancer. |
| Q41721857 | Early Detection and Risk Reduction for Familial Gynecologic Cancers |
| Q34807665 | Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer |
| Q73303564 | Effect of an in vitro fertilization program on serum CA 125, tumor-associated trypsin inhibitor, free beta-subunit of human chorionic gonadotropin, and common alpha-subunit of glycoprotein hormones |
| Q44203362 | Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination |
| Q43271918 | Effects of ovulation induction agents on ovarian surface epithelium in rats |
| Q36606365 | Egg harvesting for stem cell research: medical risks and ethical problems |
| Q84365721 | Endometrioid ovarian carcinoma in a woman with a history of infertility and multiple in‐vitro fertilization treatment cycles |
| Q34777634 | Epidemiologic perspective on immune-surveillance in cancer |
| Q33936537 | Epidemiological and genetic factors associated with ovarian cancer |
| Q34517726 | Epidemiological characteristics of ovarian cancer in Korea |
| Q38609944 | Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation |
| Q37720438 | Epidemiology of ovarian cancer: a review |
| Q57749498 | Epidemiology — identifying the causes and preventability of cancer? |
| Q40690543 | Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? |
| Q46011803 | Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. |
| Q33812564 | Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts |
| Q41457706 | Estrogen action in human ovarian cancer |
| Q46213210 | Ethnic differences in survival among women with ovarian carcinoma. |
| Q74157664 | Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study |
| Q36515505 | FSH and folliculogenesis: from physiology to ovarian stimulation |
| Q45294505 | Factors Associated with Age at Breastfeeding Cessation in Amazonian Infants: Applying a Proximal-Distal Framework |
| Q33846768 | Female infertility. |
| Q33931378 | Fertility Drugs and the Risk of Breast and Gynecologic Cancers |
| Q37972532 | Fertility Preservation Options for Females |
| Q36901734 | Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study |
| Q57561763 | Fertility drugs and breast and ovarian cancer |
| Q77292387 | Fertility drugs and malignant germ-cell tumour of ovary in pregnancy |
| Q70542134 | Fertility drugs and ovarian cancer: red alert or red herring? |
| Q53517309 | Fertility drugs and ovarian cancer: what are the practical implications of the ongoing debate? |
| Q71952585 | Fertility drugs and ovarian epithelial cancer: is there a link? |
| Q36267312 | Fertility drugs and ovarian epithelial cancer: the endometriosis hypothesis |
| Q33608317 | Fertility drugs, reproductive strategies and ovarian cancer risk. |
| Q77657933 | Follow-up of children born after in-vitro fertilisation |
| Q36385676 | Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer |
| Q44296496 | Gender of offspring and maternal ovarian cancer risk |
| Q37834134 | Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q37450640 | Genetic variation in the one-carbon transfer pathway and ovarian cancer risk |
| Q24540482 | Genetic variation in the progesterone receptor gene and ovarian cancer risk |
| Q34781250 | Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review |
| Q41733967 | Gynecologic health and disease |
| Q33830916 | HRT and cancer risk: separating fact from fiction |
| Q34935090 | HRT and cancer risks |
| Q71810810 | Harvard report on cancer prevention. Causes of human cancer. Reproductive factors |
| Q35211804 | Health expectancy and the problem of substitute morbidity |
| Q47222690 | Hegemony in a mass‐mediated society: Concordance about reproductive technologies1 |
| Q35934068 | Hereditary ovarian cancer in Ashkenazi Jews |
| Q33541940 | Hormonal interactions in ovarian cancer |
| Q74236495 | Hormonal replacement therapy and ovarian cancer |
| Q37081955 | Hormonal risk factors and invasive epithelial ovarian cancer risk by parity |
| Q35099774 | Hormonal risk factors for ovarian cancer in the Albanian case-control study |
| Q41528361 | Hormone Replacement Therapy and the Risk of Reproductive Cancers |
| Q41550777 | Hormone replacement and the menopause: a European position paper. Writing Group on Women's Health of the Fondazione Giovanni Lorenzini Medical Science Foundation |
| Q35134612 | Hormone replacement therapy and endometrial, ovarian and colorectal cancer. |
| Q36619751 | Hormone replacement therapy and risk of epithelial ovarian cancer. |
| Q53354746 | Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q71810747 | Hormones and risk of cancers of the breast and ovary |
| Q46232798 | Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro |
| Q70888519 | Human menopausal gonadotropin and the risk of epithelial ovarian cancer |
| Q41615934 | Human ovarian cancer of the surface epithelium |
| Q46226110 | Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer |
| Q34519259 | Impact and mechanistic role of oral contraceptive pills on the number and epithelial type of ovarian cortical inclusion cysts; a clinicopathology and immunohistochemical study |
| Q33648309 | In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services |
| Q43542517 | In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk |
| Q29541726 | In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients* |
| Q37639055 | In vivo evaluation of the genotoxic effects of gonadotropins on rat reticulocytes |
| Q64922061 | Incidence of intraepithelial fallopian tube neoplasias in mexican women over 40 years of age that underwent elective hysterectomy. |
| Q40621352 | Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. |
| Q71546183 | Incomplete pregnancies and risk of ovarian cancer (Washington, United States) |
| Q54760659 | Increased risk for familial ovarian cancer among Jewish women: A population-based case-control study |
| Q42772069 | Induction of ovulation |
| Q33700696 | Induction of ovulation and borderline ovarian cancer--the hormonal connection? |
| Q74245185 | Infertility treatment after conservative management of borderline ovarian tumors |
| Q58176131 | Infertility, fertility drugs, and invasive ovarian cancer: a case-control study |
| Q36267351 | Infertility: the impact of stress, the benefit of counseling |
| Q73742757 | Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve |
| Q35838031 | Is There a Relationship between Ovarian Epithelial Dysplasia and Infertility? |
| Q73271872 | Is meta-analysis a valid approach to the evaluation of small effects in observational studies? |
| Q30253059 | Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women |
| Q57560381 | Long-term effects of oral contraceptives on ovarian cancer risk |
| Q36876544 | Long-term effects of ovulation-stimulating drugs on cancer risk |
| Q37691958 | Long-term relationship of ovulation-stimulating drugs to breast cancer risk |
| Q43773486 | Low-dose oral contraceptives: Protective effect on ovarian cancer risk |
| Q40433320 | MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines |
| Q35837055 | Massive peritoneal cavity calcification in the course of advanced ovarian cancer: a case report |
| Q57951212 | Maternal considerations in formulating HIV-related breast-feeding recommendations |
| Q89442899 | Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways |
| Q36152764 | Menopausal hormone therapy |
| Q34341910 | Menopause, hormone replacement therapy and cancer |
| Q36622729 | Menstrual and reproductive factors in relation to ovarian cancer risk. |
| Q38064992 | Meta-Analysis on the Possible Association Between In Vitro Fertilization and Cancer Risk |
| Q35419057 | Microenvironment and Pathogenesis of Epithelial Ovarian Cancer |
| Q37967486 | Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form. |
| Q73454717 | Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers |
| Q34975827 | Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer |
| Q37293672 | Molecular pathogenesis of endometrial and ovarian cancer |
| Q51414790 | Mortality from breast, endometrial and ovarian cancers among grand multiparous women in Taiwan |
| Q47190779 | Multiparity activates interferon pathways in peritoneal adipose tissue and decreases susceptibility to ovarian cancer metastasis in a murine allograft model. |
| Q46849292 | Multiple gestations: some public policy issues |
| Q89975415 | Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control |
| Q58218247 | Obesity and ovarian cancer |
| Q36333904 | Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study |
| Q37594378 | Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry |
| Q36696565 | Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations |
| Q35620640 | Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition |
| Q41037130 | Oral contraceptives and cancer. A review of the evidence |
| Q34417633 | Oral contraceptives and cancer: an update |
| Q40872806 | Outcomes of Hysterectomy |
| Q34010642 | Ovarian cancer (advanced) |
| Q35552356 | Ovarian cancer and high-risk women—implications for prevention, screening, and early detection |
| Q78191124 | Ovarian cancer and infertility: a genetic link? |
| Q72753652 | Ovarian cancer and pregnancy: comment on a paper by Whittemore et al |
| Q36640904 | Ovarian cancer histology-specific incidence trends in Canada 1969-1993: age-period-cohort analyses |
| Q34034584 | Ovarian cancer in Canada. |
| Q36619469 | Ovarian cysts in women receiving tamoxifen for breast cancer |
| Q38090489 | Ovarian epithelial tumors and reproductive factors: a systematic review |
| Q47910300 | Ovarian neoplasia and subfertility treatments |
| Q58175993 | Ovarian stimulation and borderline ovarian tumors: a case-control study |
| Q83521606 | Ovarian tumours, their characterisation and origins and ovarian screening |
| Q43715513 | Ovulation induction and risk of endometrial cancer: a pilot study |
| Q41118282 | Ovulation induction, infertility, and ovarian cancer risk |
| Q34369162 | Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort |
| Q37225731 | Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. |
| Q58672382 | Pandora's box: ethics of PGD for inherited risk of late-onset disorders |
| Q37059861 | Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women |
| Q43706332 | Parity, age at first childbirth, and risk of ovarian cancer |
| Q41674950 | Pathogenesis of Ovarian Cancers |
| Q34501822 | Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications |
| Q35983656 | Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis |
| Q40274074 | Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. |
| Q33588282 | Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins |
| Q50639583 | Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome |
| Q33914363 | Pharmacoeconomic considerations in treating ovarian cancer |
| Q40923133 | Pharmacological interventions for the induction of ovulation |
| Q79118914 | Polycystic ovaries: treatment strategies |
| Q34212195 | Polycystic ovary syndrome and ovulation induction |
| Q45073049 | Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: Evidence from the Ovarian Cancer Association Consortium |
| Q24648412 | Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women |
| Q33461888 | Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer |
| Q74535190 | Postpartum maternal blood helper T (CD3+CD4+) and cytotoxic T (CD3+CD8+) cells: correlations with iron status, parity, supplement use, and lactation status |
| Q34960174 | Potential markers for detection and monitoring of ovarian cancer. |
| Q36272035 | Pregnancies resulting from in vitro matured oocytes collected from women with regular menstrual cycle |
| Q33727804 | Pregnancy saves lives |
| Q37742393 | Prevalence and determinants of cessation of exclusive breastfeeding in the early postnatal period in Sydney, Australia. |
| Q74256318 | Prevalence of ovarian endometriosis in epithelial ovarian cancer |
| Q28183254 | Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells |
| Q54651914 | Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies. |
| Q37147427 | Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens |
| Q34305384 | Protective Effect of Progesterone during Pregnancy against Ovarian Cancer |
| Q33541997 | Psychological aspects of in vitro fertilization: a review |
| Q35223096 | Racial differences in stage at diagnosis and survival from epithelial ovarian cancer: a fundamental cause of disease approach |
| Q53902954 | Re: Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in Epithelial Ovarian Cancer |
| Q48930410 | Recent Advances in Assisted Reproductive Technologies |
| Q34557167 | Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium |
| Q52193489 | Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in 932 Epithelial Ovarian Cancer |
| Q34268606 | Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. |
| Q36768628 | Reproductive characteristics in relation to ovarian cancer risk by histologic pathways |
| Q36443891 | Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study |
| Q71546186 | Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study |
| Q74106912 | Reproductive history in relation to plasma hormone levels in healthy post-menopausal women |
| Q57908386 | Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study |
| Q35053994 | Review of proteomics with applications to genetic epidemiology |
| Q53174532 | Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation |
| Q53431249 | Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study |
| Q73315390 | Risk factors for ovarian cancer in taiwan: a case–control study in a low-incidence population |
| Q36694868 | Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study |
| Q35540547 | Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort |
| Q34715540 | Risk of breast cancer following fertility treatment--a registry based cohort study of parous women in Norway |
| Q34505781 | Risk of cancer after use of fertility drugs with in-vitro fertilisation |
| Q24200437 | Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility |
| Q24241692 | Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility |
| Q46609744 | Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study |
| Q33723561 | Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery |
| Q34899934 | Risks and benefits of hormone replacement therapy: the evidence speaks |
| Q34422806 | Role of Hormone Replacement Therapy in Cancer Survivors |
| Q37453871 | Role of genetic polymorphisms and ovarian cancer susceptibility |
| Q53373961 | Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage‐dependent and ‐independent growth in human ovarian surface epithelial cell lines |
| Q36144170 | Safety of drugs used in assisted reproduction techniques |
| Q33786265 | Screening for gynecologic cancer |
| Q34628501 | Screening for ovarian cancer: recommendation statement |
| Q41713657 | Screening strategies for ovarian cancer |
| Q34310499 | Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States). |
| Q77919879 | Short- and long-term effects of ovulation induction |
| Q71949207 | Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro |
| Q41476056 | Steroid hormones and cancer: (III) observations from human subjects |
| Q73702644 | Steroidogenesis-Inducing Protein, Isolated from Human Ovarian Follicular Fluid, Is a Potent Mitogen for Cell Lines Derived from Ovarian Surface Epithelial Carcinomas |
| Q45937657 | Successful pregnancies with unstimulated cycle oocyte donation using an antagonist of gonadotropin-releasing hormone. |
| Q58579152 | The Chemoprevention of Ovarian Cancer: the Need and the Options |
| Q28066985 | The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis |
| Q35676052 | The Epidemiology of Endometrial and Ovarian Cancer |
| Q33838714 | The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition |
| Q33688763 | The adverse effects of hormone replacement therapy |
| Q40744448 | The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease |
| Q33649397 | The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks |
| Q35959353 | The genetic epidemiology of breast cancer genes |
| Q50991668 | The hen as a model of ovarian cancer |
| Q40808817 | The p53 tumor suppressor gene frequently is altered in gynecologic cancers |
| Q84972139 | The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer |
| Q47668677 | The risk for cancer among children of women who underwent in vitro fertilization |
| Q38967638 | The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up |
| Q37005150 | The stem cell debate continues: the buying and selling of eggs for research |
| Q30382011 | The utility of web mining for epidemiological research: studying the association between parity and cancer risk. |
| Q34364786 | The wisdom of hormone-replacement therapy in survivors of ovarian and endometrial cancer |
| Q50664512 | Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. |
| Q38658320 | Timing of births and oral contraceptive use influences ovarian cancer risk |
| Q62601329 | Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age |
| Q34422833 | Treatment Options for Ovarian Cancer |
| Q40927720 | Treatments for menopausal and post-menopausal problems: present and future |
| Q40058118 | Tubal ligation and ovarian cancer risk in African American women. |
| Q73936350 | Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study |
| Q37169663 | Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study |
| Q36068441 | Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis |
| Q33900722 | Tubal sterilization: focus on the U.S. experience |
| Q48960458 | Unstimulated immature oocyte retrieval: early versus midfollicular endometrial priming |
| Q34354122 | Use of clomiphene citrate in infertile women: a committee opinion |
| Q44648893 | Use of clomiphene citrate in women |
| Q34443562 | Use of fertility drugs and risk of ovarian cancer |
| Q34015977 | Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study |
| Q36153070 | Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study |
| Q38767310 | Use of fertility medications and cancer risk: a review and update |
| Q38529439 | Why have ovarian cancer mortality rates declined? Part I. Incidence |
| Q81317608 | [Update on contraception] |
Search more.